Spiramycin
Administration
- Type: macrolide antibiotic
- Dosage Forms: 250, 500
- Routes of Administration: PO, IV
- Common Trade Names: Rovamycine
Adult Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Toxoplasmosis | 1g PO q8hrs | Pregnant |
Pediatric Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Toxoplasmosis | 50-100mg/kg/day PO divided q8hrs | Pediatric/Congenital alt |
Special Populations
Pregnancy Rating
- Category B, Safe in pregnancy[1]
Lactation risk
- Distributed in breast milk
Renal Dosing
- Adult: n/a
- Pediatric: n/a
Hepatic Dosing
- Caution in hepatic impairment
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Cardiac toxicity, specifically QT prolongation
- Thrombocytopenia
- Cholestatic hepatitis
- GI toxicity, specifically acute colitis, C. diff colitis, or other intestinal injury
- Ulcerated esophagitis
- Worsening hepatic impairment in patients with pre-existing liver disease
Common
- Injection site pain
- Nausea/vomiting, diarrhea, abdominal pain
Pharmacology
- Half-life: 4.5-13.5h (increases with increasing age)
- Metabolism: Hepatic
- Excretion: Fecal (predominant), renal
Mechanism of Action
- Reversibly binds to the 50 S subunit of bacterial ribosomes, resulting in blockage of the transpeptidation or translocation reactions, inhibiting protein synthesis and subsequent cell growth[2]
Comments
- Not approved in US for standard use, though exceptions can be made to treat toxoplasmosis in pregnant women[3]
See Also
References
- ↑ Stray-Pedersen B. Treatment of toxoplasmosis in the pregnant mother and newborn child. Scand J Infect Dis 1992; 84(suppl): 23-31
- ↑ Rovamycine (spiramycin) [product monograph]. Quebec, Canada: Aventis Pharma Inc; April 2018.
- ↑ Spiramycin. Lexicomp. http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7697?searchUrl=%2Flco%2Faction%2Fsearch%3Forigin%3Dapi%26t%3Dglobalid%26q%3D6982%26nq%3Dtrue. Accessed March 5, 2020.